Опыт реализации пилотного проекта по профилактике ВПЧ инфекции вакциной Гардасил у девочек 9–14 лет в г. Санкт -Петербурге

1. Human papillomavirus vaccines WHO position paper. Weekly epidemiological record. – 10 APRIL 2009, 84th YEAR. – V. 15, № 84. – Р. 117–132.

2. Report of the meeting on HPV Vaccine Coverage and Impact Monitoring 16-17 November 2009 Geneva, Switzerland. Ordering code: WHO/IVB/10.05 May 2010, www.who.int/vaccinesdocuments/

3. The Immunological Basis for Immunization Series Module 19: Human papillomavirus infection. World Health Organization 2010, Printed in May 2011.

4. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials The Future II Study Group. www. thelancet.com – 2007. –V. 369. – June 2. – Р. 1861–1868.

5. Slade, В.A. Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine / В.A. Slade [et al.] // JAMA. – August 19, 2009. – V. 302, № 7. – Р. 750–757.

6. Fairley, C.K. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women / C.K. Fairley [et al.] // Sex. Transm. Infect. – 2009. – № 85. – Р. 499–502.

7. Donovan, B. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data / B. Donovan [et al.] // infection.thelancet. com. – 2011. – V. 2. – P. 131–137.

8. Read, T.R.H.. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme / T.R.H. Read [et al.] / Sex Transm. Infect. – 2011. – doi:10.1136/sextrans-2011-050234 group.bmj.com on October 6, 2011 – Published by sti.bmj.com Downloaded from group.bmj.com

9. Brotherton, J.M.L. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study / J.M.L. Brotherton [et al.] // thelancet.com. – 2011. – V. 377. – June 18. – P. 2085-2092.

10. Bauer, H. Evidence of hpv vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2009 / H. Bauer, G. Wright, J. Chow // Sex Transm. Infect. – July 2011. – V. 87, Suppl 1. – P. 25–26.

11. Joura, E.A. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data / E.A. Joura [et al.] // BMJ. – 2012. – V. 344. – e1401 doi: 10.1136/bmj.e1401 (Published 27 March 2012).

12. Rothman, S.M. Marketing HPV Vaccine Implications for Adolescent Heal and Medical Professionalism / S.M. Rothman, D.J. Rothman // JAMA. – August 19, 2009. – V. 302, №. 7. – Р. 781–786.

13. Гомберг, М.А. Распространенность аногенитальных бородавок в клинической практике специалистов в РФ / М.А. Гомберг, В.Н. Прилепская // Всероссийский форум «Мать и дитя», 2012.